Trial Profile

Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cholic acid (Primary)
Indications Inborn error metabolic disorders
Focus Therapeutic Use
Sponsors Asklepion Pharmaceuticals; Mirum Pharmaceuticals

Most Recent Events

17 Mar 2015 According to Asklepion Pharmaceuticals media release, US FDA has approved cholic acid [CHOLBAM] as a once daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects
03 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com